Ro Was a ‘Zombie Company.’ A Reset and GLP-1 Drugs Changed That.
Ro, formerly known as Hims & Hers, has shifted from being labelled a ‘zombie company’ to demonstrating renewed financial viability.
The story
in brief.
What happened, who it affects, and why it landed on our intelligence desk — in plain English, sixty seconds or less.
Ro, formerly known as Hims & Hers, has shifted from being labelled a ‘zombie company’ to demonstrating renewed financial viability. This turnaround is attributed to strategic operational resets and the significant integration of GLP-1 weight-loss drugs into its portfolio. The New York Times reports that this pivot has stabilised the firm’s market position, moving it away from previous distress signals. For professionals, this case study illustrates how rapid adaptation to emerging therapeutic trends and decisive corporate restructuring can reverse negative sentiment and restore investor confidence in the healthcare technology sector.
Indicative index of skill mentions in professional job postings for the field this story moves (2019 = 1)
What this means
for your career.
Every headline redistributes opportunity. Here is who this one rewards — and how to be on the right side of it.
This shift underscores the critical value of agility in healthcare and biotech sectors. Professionals must now prioritise expertise in pharmaceutical regulations, drug lifecycle management, and strategic pivots. If you work in health tech or consumer wellness, you should immediately analyse how GLP-1 therapies disrupt traditional weight management models. Smart professionals will upskill in regulatory compliance and clinical operations to navigate this new landscape. Focus on understanding the intersection of digital health platforms and novel therapeutics. By mastering these areas, you position yourself as an essential asset for companies seeking to replicate Ro’s successful transformation. Stay ahead by monitoring industry trends closely and adapting your skill set to meet the demands of an evolving pharmaceutical market.
For this story, the fields that convert it into pay are Healthcare Management, AI in Pharmaceuticals, Business and Management and Strategic Sourcing — exactly the programmes matched below. The chart shows the indicative salary uplift certified professionals report in each of those fields; every one of them is a click away, from £79, finishing in as few as 20 days.
Indicative ranges from published continuing-education salary studies, by field — each field is a recommended course below
Enrol in these
to benefit.
These programmes position you for exactly this shift — online, self-paced, and finishing with a verifiable certificate you can share the day you pass.
Best match
Certificate in Healthcare Management
Recommended
Certificate in AI in Pharmaceuticals
Recommended
Certificate in Business and Management
Recommended
Certificate in Strategic Sourcing
Launch pricing shown against standard certificate value. The fee you see today is the fee you lock in.
This briefing is based on reporting by The New York Times on 11 Nov, 13:15. Read the original coverage →
Read the news. Then outrun it.
Every LSBR programme is online, self-paced and from £79 — so a headline today can be your credential this month.